Veracyte Inc (NASDAQ:VCYT) insider John Walter Hanna, Jr. sold 18,593 shares of Veracyte stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $25.66, for a total transaction of $477,096.38. Following the sale, the insider now owns 84,085 shares in the company, valued at $2,157,621.10. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Shares of NASDAQ VCYT opened at $26.05 on Friday. The company has a market capitalization of $1.26 billion, a P/E ratio of -42.02 and a beta of 1.07. Veracyte Inc has a 52-week low of $8.77 and a 52-week high of $31.18. The company’s 50 day moving average price is $25.69 and its 200-day moving average price is $25.32.
Veracyte (NASDAQ:VCYT) last issued its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.04. The firm had revenue of $30.14 million for the quarter, compared to the consensus estimate of $29.20 million. Veracyte had a negative net margin of 11.01% and a negative return on equity of 10.26%. On average, sell-side analysts expect that Veracyte Inc will post -0.23 earnings per share for the current year.
Several research firms recently commented on VCYT. TheStreet upgraded shares of Veracyte from a “d” rating to a “c-” rating in a research report on Thursday, August 1st. ValuEngine downgraded shares of Veracyte from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 1st. BidaskClub downgraded shares of Veracyte from a “buy” rating to a “hold” rating in a research report on Thursday, September 5th. Needham & Company LLC set a $34.00 price target on shares of Veracyte and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Finally, Lake Street Capital began coverage on shares of Veracyte in a research report on Wednesday, July 31st. They issued a “buy” rating and a $35.00 price target on the stock. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $25.06.
Veracyte, Inc operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas solutions for a complex landscape in thyroid nodule diagnosis to physicians; Percepta Bronchial Genomic Classifier solution for use in lung cancer diagnosis; and Envisia Genomic Classifier solution for the diagnosis of idiopathic pulmonary fibrosis.
Further Reading: Quiet Period
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.